Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2015 1
2016 1
2017 1
2018 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Cancer immunotherapy.
Dillman RO. Dillman RO. Cancer Biother Radiopharm. 2011 Feb;26(1):1-64. doi: 10.1089/cbr.2010.0902. Cancer Biother Radiopharm. 2011. PMID: 21355777 Review.
All but two of these products are still regularly used to treat various B- and T-cell malignancies, and numerous solid tumors, including breast, lung, colorectal, prostate, melanoma, kidney, glioblastoma, bladder, and head and neck. ...The anti-CTLA-4 monoclonal ant …
All but two of these products are still regularly used to treat various B- and T-cell malignancies, and numerous solid tumors, including bre …
Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
Kraynyak KA, Bodles-Brakhop A, Bagarazzi M. Kraynyak KA, et al. Curr Top Microbiol Immunol. 2017;405:55-78. doi: 10.1007/82_2015_431. Curr Top Microbiol Immunol. 2017. PMID: 25682101 Review.
In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance of adjuvants and electroporation with emphasis on prostate, melanoma, and cervical cancer....
In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance …
Risk of Ischemic and Hemorrhagic Strokes in Occult and Manifest Cancers.
Andersen KK, Olsen TS. Andersen KK, et al. Stroke. 2018 Jul;49(7):1585-1592. doi: 10.1161/STROKEAHA.118.021373. Epub 2018 Jun 4. Stroke. 2018. PMID: 29866752
Each person with cancer was matched by age, sex, and income with 10 randomly selected persons without cancer at index date (n=2.571.260). ...For occult cancer, risk of ischemic stroke was increased for all of the smoking-related cancers, but among cancers unrelated to smok …
Each person with cancer was matched by age, sex, and income with 10 randomly selected persons without cancer at index date (n=2.571.2 …
Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review.
Rezaei A, Moqadami A, Khalaj-Kondori M. Rezaei A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2835-2848. doi: 10.1007/s00210-023-02839-1. Epub 2023 Nov 22. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37991540 Review.
Specifically, it provides a comprehensive overview of the molecular pathways by which minocycline acts on the different cancers, including ovarian, breast, glioma, colorectal, liver, pancreatic, lung, prostate, melanoma, head and neck, leukemia, and non-cancer disea …
Specifically, it provides a comprehensive overview of the molecular pathways by which minocycline acts on the different cancers, including o …
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB. Iyer G, et al. Cancer Chemother Pharmacol. 2012 Apr;69(4):1089-97. doi: 10.1007/s00280-011-1789-3. Epub 2011 Nov 29. Cancer Chemother Pharmacol. 2012. PMID: 22124669 Free PMC article. Clinical Trial.
PURPOSE: To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies. ...Of 46 eva …
PURPOSE: To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin …
Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model.
Mayzlish-Gati E, Laufer D, Grivas CF, Shaknof J, Sananes A, Bier A, Ben-Harosh S, Belausov E, Johnson MD, Artuso E, Levi O, Genin O, Prandi C, Khalaila I, Pines M, Yarden RI, Kapulnik Y, Koltai H. Mayzlish-Gati E, et al. Cancer Biol Ther. 2015;16(11):1682-8. doi: 10.1080/15384047.2015.1070982. Epub 2015 Jul 20. Cancer Biol Ther. 2015. PMID: 26192476 Free PMC article.
Furthermore, strigolactone analogs inhibited growth and survival of colon, lung, prostate, melanoma, osteosarcoma and leukemia cancer cell lines. To further examine the anti-cancer activity of SLs in vivo, we have examined their effects on growth and viability of MD …
Furthermore, strigolactone analogs inhibited growth and survival of colon, lung, prostate, melanoma, osteosarcoma and leukemia …
DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery.
Akyol Z, Çoker-Gürkan A, Arisan ED, Obakan-Yerlikaya P, Palavan-Ünsal N. Akyol Z, et al. Biomed Pharmacother. 2016 Dec;84:2029-2041. doi: 10.1016/j.biopha.2016.11.016. Epub 2016 Nov 20. Biomed Pharmacother. 2016. PMID: 27881234
N1,N11-diethylnorspermine (DENSpm), a polyamine analogue, which is a promising drug candidate induced-cell cycle arrest and apoptosis in various cancer cells such as prostate, melanoma, colon and breast cancer cells via activated polyamine catabolism and reactive ox …
N1,N11-diethylnorspermine (DENSpm), a polyamine analogue, which is a promising drug candidate induced-cell cycle arrest and apoptosis in var …